Furthermore, the combination of a PARP inhibitor and an NAMPT inhibitor initiated DNA degradation and caspase-3 cleavage, leading to apoptosis of ovarian cancer cells [65]. This evidence concerns the gene PARP1 and ovarian carcinoma.